跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 智宇
教授
臨床醫學研究所
https://orcid.org/0000-0001-9899-3159
電話
02-28767000 #66522
電子郵件
cyyang3
vghtpe.gov
tw
網站
https://icm.nycu.edu.tw/%e6%a5%8a%e6%99%ba%e5%ae%87-yang-chih-yu/
h-index
h10-index
h5-index
1962
引文
25
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1470
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
681
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2025
每年研究成果
概覽
指紋
網路
研究成果
(116)
類似的個人檔案
(6)
指紋
查看啟用 Chih-Yu Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Maintenance Hemodialysis Patients
58%
Hemodialysis Patients
57%
Chronic Kidney Disease
54%
Arteriovenous Fistula
53%
Confidence Interval
49%
Acute Kidney Injury
45%
Risk Factors
40%
Hazard Ratio
40%
Chronic Kidney Disease Patients
30%
Hemodialysis
30%
All-cause Mortality
29%
Renal Function
28%
Survivors
28%
Clinical Outcomes
28%
End-stage Kidney Disease
26%
Taiwan
23%
Sepsis
23%
Renal Outcome
23%
Mortality Risk
22%
Dialysis
21%
Angiotensin Receptor Blockers
20%
End-stage Renal Disease
20%
Hospitalization
19%
Nested Case-control Study
18%
Lupus Nephritis
18%
Kidney
18%
Long-term Hemodialysis
17%
Uremic Patients
16%
Protein-to-creatinine Ratio
16%
Angiotensin-converting Enzyme Inhibitor (ACEi)
15%
Erythropoiesis-stimulating Agents
15%
Odds Ratio
15%
Dialysis Patients
15%
Proteinuria
15%
Prospective Observational Study
14%
Pneumocystis Jirovecii
14%
Serum Uric Acid
13%
Anemia
13%
Indoxyl Sulfate
13%
Peritoneal Dialysis Patients
13%
Renal Transplant Recipients
13%
Type 2 Diabetic Patients
13%
Interstitial Fibrosis
12%
Mesenchymal Stem Cells
12%
Adverse Cardiac Events
12%
Chinese Patients
12%
Minimal Change Disease
12%
Nautilus
12%
BK Virus Nephropathy
12%
National Cohort Study
12%
Medicine and Dentistry
Hemodialysis
100%
Arteriovenous Fistula
55%
Chronic Kidney Disease
45%
End Stage Renal Disease
44%
Acute Kidney Injury
42%
Hazard Ratio
36%
Kidney Function
36%
Infection
24%
Sepsis
23%
Immunosuppressant
22%
Kidney Graft
21%
Creatinine
19%
Peritoneal Dialysis
19%
ACE Inhibitor
18%
Angiotensin Receptor Antagonist
18%
Glomerular Filtration Rate
15%
Vascular Access
15%
Cohort Analysis
15%
Light Chain
15%
Proportional Hazards Model
14%
Cohort Study
14%
Cardiovascular System
14%
Anemia
14%
Nephropathy
14%
Renal Biopsy
13%
Blood Vessel Calcification
13%
Renin Angiotensin Aldosterone System
13%
Blood Flow
13%
Pneumocystis Pneumonia
12%
Odds Ratio
12%
Photoelectric Plethysmography
12%
Patient with Hypertension
12%
Bone Development
12%
Parathyroidectomy
12%
Systemic Lupus Erythematosus
12%
ATTR Amyloidosis
12%
Lupus Nephritis
12%
Cognitive Defect
12%
Amyloidosis
12%
Idiopathic Pulmonary Fibrosis
12%
Pyrophosphate
12%
Physical Activity
12%
Out of Hospital Cardiac Arrest
12%
Technetium-99
12%
All Cause Mortality
12%
Respiratory Failure
11%
Case Presentation
10%
Continuous Erythropoiesis Receptor Activator
10%
Iron
10%
Drug Dose Reduction
10%
